Posts tagged as

Prostate Cancer Research

COMPPARE Achieves 75% Enrollment Milestone

The COMPPARE Coordinating Center announced today that the study achieved 75% enrollment on May 3, 2022. COMPPARE realized both a remarkable overall accrual rate and a exceptional accrual rate of minorities, despite the ongoing challenges presented by COVID-19. In fact, the study stands to become a model for patient-centric clinical…

COMPPARE Reaches Its Pragmatic Proton Patient Enrollment Goal

The COMPPARE Coordinating Center announced on September 1, 2021 that the study had reached its Pragmatic Proton enrollment goal of 900 patients, completing and closing that arm of the proton cohort. The 900th patient was enrolled by the Proton Therapy Treatment & Research Center of the Loma Linda University Medical…

COMPPARE Enrolls 1,000 Patients

The COMPPARE team was pleased to announce on November 13, 2020 that the study had enrolled 1,000 patients, one-third of its 3,000-patient goal. COMPPARE’s partner site, the James M. Slater, MD Proton Treatment & Research Center, Loma Linda, CA, enrolled the 1,000th patient. COMPPARE stands for “A Prospective COMparative Study…

Patient Information

English and spanish versions COMPPARE Brochures Learn why this study will help future patients make evidence-based treatment decisions.

COMPPARE: A Path to Improve Future Health Outcomes for Men with Prostate Cancer

Thank you for your interest in the COMPPARE study. COMPPARE stands for “A Prospective COMparative Study of Outcomes with Proton and Photon RAdiation in PRostate CancEr (COMPPARE).” This study, which is funded by the Patient-Centered Outcomes Research Institute (PCORI) and approved by the University of Florida Institutional Review Board…

About

Study Overview What is COMPPARE? What is the goal of COMPPARE? Who is eligible for COMPPARE? How does participation in COMPPARE work? Why is COMPPARE important for patients? What is the benefit of participating in COMPPARE? How can I learn more about…

Contact the COMPPARE Team